ArticleDrug and alcohol dependence reports2026
Xylazine in Ohio: Insights from individuals with criminal legal system involvement and a history of illicit stimulant use.
Article in Drug and alcohol dependence reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Xylazine, a non-opioid sedative not approved for human use, poses serious health risks. It is primarily found in illicitly manufactured fentanyl, but xylazine-fentanyl combinations also appear as illicit stimulant adulterants. Although strategies exist to reduce the risk of xylazine-related harms, some high-risk populations may be unaware of the drug, including people with recent criminal legal system involvement who use illicit stimulants. Methods: A cross-sectional electronic survey was conducted in Ohio in October 2024 to assess xylazine-related knowledge, attitudes, and behaviors among people with criminal legal system involvement and prior illicit stimulant use. Participants were recruited from Ohio courts. Results: Among 229 respondents (43.5% response rate), 42.4% had heard of xylazine. The sample was 54.6% female, 83.3% White, 3.1% Hispanic or Latino, and mean age was 38.5 years (SD = 9.4). Individuals who had heard of xylazine were more likely to have used fentanyl (35.1% vs. 7.1%) or heroin (35.5% vs. 2.4%) in the past 6 months than those who had not heard of it. Most respondents (75.1%) indicated it was "very important" to know if xylazine is in their drugs and 66.4% would be "very" or "somewhat likely" to use xylazine test strips, if available at no cost. Among people who had heard of xylazine, 83.5% did not want to use xylazine and try to avoid it. Conclusions: Most respondents were unaware of xylazine, despite its prevalence in Ohio. Xylazine education and easy access to harm reduction tools are critical for preventing xylazine-related harms among this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.